MedTrace Logo

Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years

NCT01764204 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30840

Last updated 2018-02-19

No results posted yet for this study

Summary

To highlight the incidence of adverse reactions of Qingkailing Injection.

Conditions

  • Adverse Drug Events
  • Adverse Drug Reactions

Interventions

DRUG

Qingkailing Injection

Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.

Sponsors & Collaborators

  • China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Zhong Wang, Ph.D., M.D. · Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

Eligibility

Min Age
1 Year
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2017-12-31
Completion
2018-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01764204 on ClinicalTrials.gov